We report a rare case of malignant mesothelioma of the tunica vaginalis testis. A 67-year-old man was hospitalized with a complaint of swelling on the right side of the scrotal contents. Right high orchiectomy was performed, and the pathological examination revealed malignant mesothelioma of the tunica vaginalis testis. The surgery was thought to have been radical, but 4 months post-operation, local recurrence in the inguinal skin and distant metastasis in the para-aortic lymph node were found. The tumors were treated by surgical resection and radiation therapy. Two months after the second treatment, multiple lung metastasis and a second local recurrence in the inguinal skin were found. High-dose chemotherapy with cisplatin and doxorubicin was performed, but no change was confirmed after 4 weeks. The disease progressed, resulting in death within 8 months of diagnosis. The response of mesothelioma to chemotherapy is thought to be poor histologically as indicated by this case and previously reported cases, so initial radical surgery and adjuvant procedures soon after diagnosis are necessary to achieve cure.

Keywords:
Malignant mesothelioma, Cisplatin, Doxorubicin
This content is only available via PDF.
© 1995 S. Karger AG, Basel
1995
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.